Azitra, Inc., a clinical stage biopharmaceutical company, will present at the 2025 American Society of Clinical Oncology Annual Meeting, taking place from May 30 to June 3, 2025, in Chicago. They will showcase a poster on their Phase 1/2 clinical trial of ATR04-484, focusing on the treatment of EGFR inhibitor-induced dermal toxicity with a novel _Staphylococcus epidermidis_ compound.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.